| abstract |
Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include a first F protein polypeptide domain, a G protein polypeptide domain, and a second F protein polypeptide domain in the N-terminal to C-terminal direction. The disclosure also provides nucleic acids encoding chimeric RSV polypeptides, and pharmaceutical compositions comprising the chimeric RSV polypeptides, and methods for their production and use. |